Marker Therapeutics, Inc. — Director's Dealing 2018

Oct 23, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-10-19

Reporting Person: Loiacono Michael (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-19	Employee Stock Option (Right to Buy)	$9.18	A	300000	Acquired	2028-10-19	Common Stock (300000)	Direct

Footnotes

F1: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended. These shares vest in monthly installments over a four year period upon the continued employment of the Reporting Person by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018.